

Achieving High Adolescent HPV Vaccination Coverage

ANNA-LISA M. FARMAR, MD, MPH
National Vaccine Advisory Committee Meeting
February 7, 2018



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

DISCLOSURES

I have no actual or potential conflicts of interest in relation to this presentation.



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

OVERVIEW

- Introduction
- Objectives
- Methods
- Results
- Conclusions



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

INTRODUCTION

- HPV is the most common sexually transmitted infection in the US
- Affects ~76 million people
- 33,000 cancer cases per year



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

INTRODUCTION

Despite the Advisory Committee on Immunization Practice (ACIP) recommendation for routine adolescent HPV vaccination as well as a Healthy People 2020 goal of 80% vaccine coverage in adolescents, HPV vaccination rates have lagged behind those of meningococcal conjugate vaccine (MCV) and tetanus, diphtheria and acellular pertussis vaccine (Tdap).



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

INTRODUCTION - BARRIERS

- **Patient characteristics:**
 - Younger age
 - Male
 - Lack of insurance
 - Poor knowledge of HPV disease and vaccine
- **Provider factors:**
 - Lack of a strong recommendation for the vaccine
 - Financial concerns
 - Missed opportunities for vaccination



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

INTRODUCTION - BARRIERS

- **Systems-level barriers:**
 - Missed opportunities for vaccination
 - Concerns about reimbursement, insurance coverage
 - School systems' lack of mandate for HPV



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

INTRODUCTION

The vaccination program at Denver Health addresses the provider factors of **giving a strong recommendation for all vaccines**, including HPV, and the systems-level factor of **minimizing missed opportunities**.



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

OBJECTIVES

1. Describe tactics used to achieve high HPV vaccination coverage in a large urban safety-net health care system.
1. Examine factors affecting HPV vaccine uptake.



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

METHODS - SETTING

- Urban safety-net integrated health system
- Serving:
 - > 50% of the uninsured and Medicaid population in Denver
 - 40% of the city's children
 - 43% of the Denver Hispanic community
 - 33% of the Denver African-American community
 - 17,000 adolescents annually



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

METHODS - SETTING

- **Pediatric/Adolescent Population (0-18y):**
 - 79% Medicaid
 - 5% CHP+
 - 5% Uninsured
 - 9% Private insurance
- **Adolescent vaccine delivery sites:**
 - 8 FQHCs
 - 17 School-based health centers (SBHCs)
 - Denver Public Health Immunization Clinic



METHODS – DATA SOURCES

- Vaccine registry and utilization statistics were used to determine vaccination coverage rates in adolescents ages 13–17 years from 2004-2014 for Tdap, MCV and HPV (1 & 3 doses).
- Data were examined separately for males and females.
- Rates were compared with national data reported by the Centers for Disease Control and Prevention.



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

METHODS

Vaccine Delivery Methods:

Involves several steps that result in a “bundling” of the three adolescent vaccinations (Tdap, MCV and HPV)

- Standing order for immunizations
- Medical assistants check the vaccine registry for recommended vaccines at every visit (sick or well)
- Vaccines are given early in the visit
- Providers present Tdap, MCV and HPV as standard immunizations recommended for the adolescents' health



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

METHODS

Routine use of vaccine registries:

- **Vax Trax**
 - Internally developed immunization registry
 - Multiple functions: recommend, vaccine inventory, historic information storage
 - Contraindications & refusals
- **CIIS:** state registry
- MAs use the recommend functionality to create list of specific vaccines for which the patient is due



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

METHODS

Standing Order for Vaccinations:

- Recommend list becomes standing order
- Signature required only for vaccines given outside standard of care
- Vaccines may be given before or after provider sees patient



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

METHODS

Presenting Vaccines in Standard Bundle:

- Providers encouraged to present all 3 adolescent vaccines together, rather than as required vs. optional
- Weekly educational meetings
 - QI data
 - Addressing vaccine refusal
- Provider- and clinic-level report cards



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY



HPV Rates By Medical Home and PCP

Medical Home: DH PAV G PEDS MEDICAL HOME

Age Group: 11-18 years

pcp	Total	Never Had Vaccine	%	Due For 2nd	%	Due For 3rd	%	Complete	%
LEV, JERUSHA P	206	25	12.14%	35	16.99%	4	1.94%	142	68.93%
WILLIAMS, JOSHUA T	6	0	0.00%	5	83.33%	0	0.00%	1	16.67%
ANDERSON, MARK E	275	28	10.18%	58	21.09%	7	2.55%	182	66.18%
FLORES, ANA I	282	27	9.57%	44	15.60%	4	1.42%	207	73.40%
HARASAKI, CARA E	18	2	11.11%	2	11.11%	0	0.00%	14	77.78%
VANDERLIET, ELIZABETH J	7	1	14.29%	1	14.29%	0	0.00%	5	71.43%
MILLER, PHILIP K	43	3	6.98%	14	32.56%	0	0.00%	26	60.47%
MONTHATHONG, LAURA J	268	39	14.55%	48	17.91%	4	1.49%	177	66.04%
ANDERSON, LAUREN R	6	0	0.00%	2	33.33%	0	0.00%	4	66.67%
FARMAR, ANNA-LISA M	176	18	10.23%	46	26.14%	1	0.57%	111	63.07%
MCILHANY, CATHERINE L	225	32	14.22%	45	20.00%	4	1.78%	144	64.00%
PROVIDER NOT IN SYSTEM	15	7	46.67%	3	20.00%	0	0.00%	5	33.33%
FREEMAN, REBECCA K	268	34	12.69%	52	19.40%	4	1.49%	178	66.42%
ROQUES ESCOLAR, MARIA	318	30	9.43%	63	19.81%	3	0.94%	222	69.81%
SYLVESTER, KIMBERLY A	348	47	13.51%	80	22.99%	8	2.30%	213	61.21%



METHODS

Other Interventions:

- SBHC vaccination drives
- QI measure focused on improving preventive visit rates
- Offering vaccines at every visit even if previously declined



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

METHODS – SUMMARY

- Routine use of a robust immunization registry for multiple functions, including recording vaccine history and recommending needed vaccines at every visit
- Medical Assistants check vaccine registry for recommended vaccines at every visit
- Standing order for routine immunizations
- Vaccines are given early in the visit when possible, to allow time to observe for immediate side effects such as syncope
- Education for providers to present Tdap, MCV, and HPV as a standard “bundle” of adolescent immunizations
- Provider-level “report cards” with adolescent vaccination coverage rates
- Vaccination drives at School Based Health Clinics



RESULTS

- Rates for Tdap, MCV and HPV rose steadily from 2004 to 2014.
- In 2014 (n=11,463), HPV coverage of ≥ 1 dose in females was 89.8% and in males was 89.3%, compared to national rates of 57.3% and 34.6%, respectively.



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

RESULTS

- HPV completion rates (3 doses) were 66.8% for females and 59.9% for males, versus 39.7% and 21.6% nationally.
- For both genders, Tdap coverage was 95.5% (87.6% nationally) and MCV coverage was 93.6% (74.0% nationally).




DENVER HEALTH


est. 1860

FOR LIFE'S JOURNEY

Chart 1: Denver Health Immunization Rates For Teens 13-17 (2004-2013)



National, State, and Denver Health Adolescent Immunization Rates (2013)



RESULTS

Adjusted Odds for receiving ≥ 3 Doses HPV

Characteristic		Odds Ratio	95% Wald Confidence Interval	
Age (Linear)		1.17	1.13	1.20
Gender	Male	1.00	-	-
	Female	1.74	1.61	1.89
Race	White	1.00	-	-
	Black	1.13	0.97	1.33
	Latino	1.77	1.54	2.03
	Other	0.93	0.72	1.19
Language	English	1.00	-	-
	Spanish	1.26	1.15	1.38
	Other	2.16	1.68	2.78
FPL	> 200%	1.00	-	-
	$\leq 200\%$	1.43	1.10	1.87
	Unknown	0.67	0.50	0.90



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

RESULTS - UPDATE

- Most recent data (through January 2018):
 - **HPV 1 dose:**
 - **Female:** 82.4% (↓) (65%)
 - **Male:** 83.3% (↓) (56%)
 - **HPV \geq 2 doses:**
 - **Female:** 63.5% (↓) (49.5%)
 - **Male:** 62.5% (↑) (37.5%)
- **Adult rates:**
 - Adult coverage rates (2018 – 19-26 year olds)
51.4%



CONCLUSIONS

Through low-cost, system-wide standard procedures, Denver Health achieved adolescent vaccination rates well above national coverage rates and surpassed the Healthy People 2020 goal of 80%, especially for HPV. Avoiding missed opportunities for vaccination and normalizing the HPV vaccine were key procedures that likely contributed to high coverage rates.



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

ACKNOWLEDGMENTS

- Kathryn Love-Osborne, MD
- Katherine Chichester, RN
- Kristin Breslin, MPH
- Kristi Bronkan, PharmD
- Simon Hambidge, MD, PhD
- Providers and MAs of Denver Health's pediatric clinics



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

REFERENCES

1. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. *Sex Transm Dis*. 2013 Mar;40(3):187-93. doi: 10.1097/OLQ.0b013e318286bb53.
2. Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers – United States, 2004-2008. *MMWR Morb Mortal Wkly Rep*. 2012 Apr 20;61:258-61.
3. Elam-Evans LD, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years – United States, 2013. *MMWR Morb Mortal Wkly Rep*. 2014 Jul 25;63(29):625-33.
4. Alexander AB, Best C, Stupiansky N, Zimet GD. A model of health care provider decision making about HPV vaccination in adolescent males. *Vaccine*. 2015 Aug 7;33(33):4081-6. doi: 10.1016/j.vaccine.2015.06.085.
5. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. *JAMA Pediatr* 2014 Jan;168(1):76-82. doi: 10.1001/jamapediatrics.2013-2752.7.
6. Hendry M, Lewis R, Clements A, et al. “HPV? Never heard of it!”: A systematic review of girls’ and parents’ information needs, views and preferences about human papillomavirus vaccination. *Vaccine*. 2013 Oct 25;31(45):5152-67. doi: 10.1016/j.vaccine.2013.08.091.
7. Smith PJ, Chu SY, Barker LE. Children Who Have Received No Vaccines: Who Are They and Where Do They Live? *Pediatrics* 2004 Jul;114(1):187-95.
8. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years – United States, 2014. *MMWR Morb Mortal Wkly Rep*. 2015 Jul 31;64(29):784-92.
9. Kester LM, Zimet GD, Fortenberry JD, et al. A National Study of HPV Vaccination of Adolescent Girls: Rates, Predictors, and Reasons for Non-Vaccination. *Matern Child Health J* 2013 Jul;17(5):879-85. doi: 10.1007/s10995-012-1066-z.
10. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. *Clin Pediatr (Phila)*. 2013 Feb;52(2):162-70. doi: 10.1177/0009922812468208. Epub 2012 Dec 6.



REFERENCES

11. Monnat SM, Rhubart DC, Wallington SF. Differences in Human Papillomavirus Vaccination Among Adolescent Girls in Metropolitan Versus Non-metropolitan Areas: Considering the Moderating Roles of Maternal Socioeconomic Status and Health Care Access. *Matern Child Health J* 2015 Oct 28. [Epub ahead of print]
12. Rosenthal SL, Rupp R, Zimet GD, et al. Uptake of HPV Vaccine: Demographics, Sexual History and Values, Parenting Style, and Vaccine Attitudes. *J Adolesc Health* 2008 Sep;43(3):239-45. doi: 10.1016/j.jadohealth.2008.06.009.
13. Rosenthal SL, Weiss TW, Zimet GD, et al. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. *Vaccine* 2011 Jan 29;29(5):890-5. doi: 10.1016/j.vaccine.2009.12.063. Epub 2010 Jan 5.
14. Clark SJ, Cowan AE, Filipp SL, et al. Parent Perception of Provider Interactions Influences HPV Vaccination Status of Adolescent Females. *Clinical Pediatrics* 2015 Oct 7. pii: 0009922815610629. . [Epub ahead of print]
15. Perkins RB, Clarck JA, Apte G, et al. Missed Opportunities for HPV Vaccination in Adolescent Girls: A Qualitative Study. *Pediatrics* 2014 Sep;134(3):e666-74. doi: 10.1542/peds.2014-0442.
16. Schluterman NH, Terplan M, Lydecker AD, Tracy JK. Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. *Vaccine* 2011 May 12;29(21):3767-72. doi: 10.1016/j.vaccine.2011.03.032. Epub 2011 Apr 6.
17. Stokley S, Jeyarajah J, Yankey D, et al. Human Papillomavirus Vaccination Coverage Among Adolescents, 2007-2013, and Postlicensure Vaccine Safety Monitoring, 2006-2014 – United States. *MMWR Morb Mortal Wkly Rep*. 2014 Jul 25;63(29):620-24.
18. Alexander AB, Stupiansky NW, Ott MA, et al. What parents and their adolescent sons suggest for male HPV vaccine messaging. *Health Psychol*. 2014 May;33(5):448-56. doi: 10.1037/a0033863.
19. Gabow PA, Mehler PS. A Broad and Structured Approach to Improving Patient Safety and Quality: Lessons from Denver Health. *Health Affairs* 2011 Apr;30(4):612-618. doi: 10.1377/hlthaff.2011.0042.
20. Davidson AJ, Melinkovich P, Beatty BL, et al. Immunization Registry Accuracy: Improvement with Progressive Clinical Application. *Am J Prev Med* 2003;24(3). doi: 10.1016/S0749-3793(02)00638-4.





DENVER HEALTH™

est. 1860

FOR LIFE'S JOURNEY

Anna-Lisa M. Farmer, MD, MPH
Assistant Professor – Pediatrics
Denver Health Medical Center
University of Colorado
301 W. 6th Ave, MC 1911
Denver, CO 80204
anna-lisa.farmer@dhha.org
(303)602-8385